Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel Free BNTC Stock Alerts

Benitec Biopharma (BNTC) Financials

Benitec Biopharma logo
$11.97 -0.81 (-6.34%)
Closing price 07/20/2026 04:00 PM Eastern
Extended Trading
$11.97 0.00 (0.00%)
As of 07/20/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Benitec Biopharma

Annual Income Statements for Benitec Biopharma

This table shows Benitec Biopharma's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025
Net Income / (Loss) Attributable to Common Shareholders		 2.61 -8.27 -14 -18 -20 -22 -38
Consolidated Net Income / (Loss)		 2.61 -8.27 -14 -18 -20 -22 -38
Net Income / (Loss) Continuing Operations		 2.61 -8.27 -14 -18 -20 -22 -38
Total Pre-Tax Income 		2.61 -8.27 -14 -18 -20 -22 -38
Total Operating Income		 2.58 -8.28 -14 -18 -19 -22 -42
Total Gross Profit		 12 0.10 0.06 0.07 0.08 0.00 0.00
Total Revenue		 12 0.10 0.06 0.07 0.08 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 9.62 8.38 14 18 19 22 42
Selling, General & Admin Expense		 4.61 5.57 6.51 6.65 6.38 6.99 23
Research & Development Expense		 4.57 3.00 7.02 11 13 16 18
Other Operating Expenses / (Income)		 0.44 -0.19 0.12 0.01 0.00 -0.11 0.00
Total Other Income / (Expense), net		 0.03 0.01 -0.29 -0.35 -0.48 0.74 3.85
Interest Expense		 - - - - - 0.00 -0.76
Interest & Investment Income		 0.12 0.06 -0.01 -0.03 -0.03 0.90 3.29
Other Income / (Expense), net		 -0.10 -0.06 -0.28 -0.32 -0.45 -0.17 -0.20
Preferred Stock Dividends Declared		 - - - - - 0.62 0.00
Basic Earnings per Share		 $3.05 ($8.10) ($3.23) ($37.88) ($14.12) ($1.22) ($1.05)
Weighted Average Basic Shares Outstanding		 856.77K 1.02M 4.30M 480.69K 1.39M 18.36M 36.21M
Diluted Earnings per Share		 $3.05 ($8.10) ($3.23) ($37.88) ($14.12) ($1.22) ($1.05)
Weighted Average Diluted Shares Outstanding		 856.77K 1.02M 4.30M 480.69K 1.39M 18.36M 36.21M
Weighted Average Basic & Diluted Shares Outstanding		 856.77K 1.02M 4.30M 8.17M 2.55M 10.56M 26.25M

Quarterly Income Statements for Benitec Biopharma

This table shows Benitec Biopharma's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q3 2025 Q1 2026 Q3 2026
Period end date 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2024 3/31/2024 6/30/2024 9/30/2024 3/31/2025 9/30/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -5.41 -4.40 -4.66 -6.57 -7.36 -4.28 -5.34 -5.06 -15 -8.97 -12
Consolidated Net Income / (Loss)		 -5.41 -4.40 -4.66 -5.95 -7.36 -4.28 -4.72 -5.06 -15 -8.97 -12
Net Income / (Loss) Continuing Operations		 -5.41 -4.40 -4.66 -5.95 -7.36 -4.28 -4.72 -5.06 -15 -8.97 -12
Total Pre-Tax Income 		-5.41 -4.40 -4.66 -5.95 -7.36 -4.28 -4.72 -5.06 -15 -8.97 -12
Total Operating Income		 -5.61 -4.34 -4.55 -5.87 -8.61 -4.14 -5.55 -5.79 -15 -9.80 -14
Total Gross Profit		 0.01 0.05 0.01 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00
Total Revenue		 0.01 0.05 0.01 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00
Total Operating Expenses		 5.62 4.40 4.56 5.87 8.61 4.14 5.55 5.79 15 9.80 14
Selling, General & Admin Expense		 1.86 1.23 1.37 1.55 3.54 1.58 2.04 2.21 8.84 6.43 7.28
Research & Development Expense		 3.76 3.17 3.19 4.43 5.07 2.57 3.51 3.59 6.50 3.37 6.30
Total Other Income / (Expense), net		 0.20 -0.06 -0.11 -0.08 1.25 -0.14 0.83 0.73 0.83 0.84 1.65
Interest Expense		 - - - - -0.76 0.00 - - 0.00 - 0.00
Interest & Investment Income		 -0.01 -0.01 -0.01 -0.01 0.82 -0.00 0.92 0.60 0.82 1.01 1.59
Other Income / (Expense), net		 0.21 -0.05 -0.10 -0.07 -0.33 -0.13 -0.09 0.13 0.01 -0.17 0.05
Basic Earnings per Share		 ($3.34) ($2.67) ($3.36) ($3.05) ($0.33) ($0.23) ($1.31) ($0.18) ($0.38) ($0.22) ($0.24)
Weighted Average Basic Shares Outstanding		 1.62M 1.65M 1.39M 2.16M 22.08M 18.28M 4.06M 27.88M 38.60M 41.52M 49.39M
Diluted Earnings per Share		 ($3.34) ($2.67) ($3.36) ($3.05) ($0.33) ($0.23) ($1.31) ($0.18) ($0.38) ($0.22) ($0.24)
Weighted Average Diluted Shares Outstanding		 1.62M 1.65M 1.39M 2.16M 22.08M 18.28M 4.06M 27.88M 38.60M 41.52M 49.39M
Weighted Average Basic & Diluted Shares Outstanding		 27.98M 27.98M 2.55M 2.57M 23.45M 9.37M 10.56M 23.22M 25.60M 33.86M 34.35M

Annual Cash Flow Statements for Benitec Biopharma

This table details how cash moves in and out of Benitec Biopharma's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025
Net Change in Cash & Equivalents		 4.39 -5.86 9.97 -16 -1.59 48 47
Net Cash From Operating Activities		 4.79 -7.54 -13 -16 -18 -19 -24
Net Cash From Continuing Operating Activities		 4.79 -7.54 -13 -16 -18 -19 -24
Net Income / (Loss) Continuing Operations		 2.61 -8.27 -14 -18 -20 -22 -38
Consolidated Net Income / (Loss)		 2.61 -8.27 -14 -18 -20 -22 -38
Depreciation Expense		 0.16 0.19 0.23 0.17 0.14 0.09 0.07
Amortization Expense		 0.00 0.18 0.19 0.23 0.25 0.26 0.33
Non-Cash Adjustments To Reconcile Net Income		 0.70 0.07 0.43 0.88 0.46 0.83 16
Changes in Operating Assets and Liabilities, net		 1.32 0.30 0.20 1.04 0.71 1.17 -2.37
Net Cash From Investing Activities		 -0.40 -0.09 -0.22 -0.01 -0.00 -0.18 -0.02
Net Cash From Continuing Investing Activities		 -0.40 -0.09 -0.22 -0.01 -0.00 -0.18 -0.02
Purchase of Property, Plant & Equipment		 -0.40 -0.10 -0.22 -0.01 -0.00 -0.18 -0.02
Net Cash From Financing Activities		 0.00 1.77 23 0.00 16 68 70
Net Cash From Continuing Financing Activities		 0.00 1.77 23 0.00 16 68 70
Repurchase of Common Equity		 0.00 -0.48 -3.23 0.00 -1.87 -5.89 -2.32
Issuance of Common Equity		 0.00 2.25 26 0.00 18 71 30
Other Financing Activities, net		 - - - - - 3.04 42
Effect of Exchange Rate Changes		 - - - 0.20 0.41 -0.01 0.05

Quarterly Cash Flow Statements for Benitec Biopharma

This table details how cash moves in and out of Benitec Biopharma's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q4 2025 Q1 2026
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 6/30/2025 9/30/2025
Net Change in Cash & Equivalents		 12 -6.00 -3.99 -4.08 23 -5.49 -6.23 37 17 -5.79 -3.27
Net Cash From Operating Activities		 -4.05 -5.84 -4.03 -4.10 -4.58 -5.37 -6.17 -3.29 -4.59 -8.21 -3.35
Net Cash From Continuing Operating Activities		 -4.05 -5.84 -4.03 -4.10 -4.58 -5.37 -6.17 -3.29 -4.59 -8.21 -3.35
Net Income / (Loss) Continuing Operations		 -5.09 -5.41 -4.40 -4.66 -5.95 -6.80 -4.28 -4.72 -5.06 -16 -8.97
Consolidated Net Income / (Loss)		 -5.09 -5.41 -4.40 -4.66 -5.95 -6.80 -4.28 -4.72 -5.06 -16 -8.97
Depreciation Expense		 0.04 0.04 0.03 0.02 0.02 0.02 0.03 0.03 0.03 0.01 0.01
Amortization Expense		 0.06 0.06 0.06 0.06 0.06 0.06 0.07 0.07 0.07 0.10 0.11
Non-Cash Adjustments To Reconcile Net Income		 0.24 -0.11 0.01 0.31 0.09 0.09 0.19 0.45 0.36 13 5.18
Changes in Operating Assets and Liabilities, net		 0.71 -0.43 0.26 0.17 1.20 1.26 -2.17 0.88 0.02 -5.28 0.32
Net Cash From Investing Activities		 0.00 - - -0.00 0.00 - -0.18 - 0.00 - 0.00
Net Cash From Continuing Investing Activities		 0.00 - - -0.00 0.00 - -0.18 - 0.00 - 0.00
Net Cash From Financing Activities		 16 - - - 28 0.04 - 40 22 2.54 0.00
Net Cash From Continuing Financing Activities		 16 - - - 28 0.04 - 40 22 2.54 0.00
Other Financing Activities, net		 - - - - 31 0.04 - - 22 2.62 0.00
Effect of Exchange Rate Changes		 0.50 -0.15 0.04 0.02 0.05 -0.16 0.12 -0.01 -0.10 -0.12 0.09

Annual Balance Sheets for Benitec Biopharma

This table presents Benitec Biopharma's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025
Total Assets		 19 12 21 5.97 4.46 52 100
Total Current Assets		 19 11 21 4.82 3.73 52 99
Cash & Equivalents		 16 9.80 20 4.06 2.48 51 98
Restricted Cash		 - - 0.02 0.01 0.01 0.06 0.11
Accounts Receivable		 2.54 0.06 0.03 0.00 0.06 0.23 0.03
Prepaid Expenses		 - - 0.80 0.74 1.18 0.52 0.63
Plant, Property, & Equipment, net		 0.47 0.37 0.38 0.22 0.09 0.18 0.13
Total Noncurrent Assets		 0.01 0.40 0.40 0.93 0.65 0.36 0.94
Other Noncurrent Operating Assets		 0.01 0.40 0.40 0.93 0.65 0.36 0.94
Total Liabilities & Shareholders' Equity		 19 12 21 5.97 4.46 52 100
Total Liabilities		 2.64 1.35 1.37 3.09 4.26 4.96 2.30
Total Current Liabilities		 2.64 1.14 1.37 2.53 3.98 4.92 1.80
Accounts Payable		 2.49 0.74 0.88 1.88 3.23 4.17 1.02
Current Employee Benefit Liabilities		 0.15 0.20 0.28 0.40 0.47 0.48 0.43
Other Current Liabilities		 0.00 0.19 0.21 0.25 0.28 0.28 0.35
Total Noncurrent Liabilities		 0.00 0.21 0.00 0.56 0.28 0.04 0.50
Other Noncurrent Operating Liabilities		 0.00 0.21 0.00 0.56 0.28 0.00 0.50
Total Equity & Noncontrolling Interests		 17 10 20 2.88 0.20 47 97
Total Preferred & Common Equity		 17 10 20 2.88 0.20 47 97
Preferred Stock		 - - - - - 0.00 0.00
Total Common Equity		 17 10 20 2.88 0.20 47 97
Common Stock		 127 129 152 152 169 238 326
Retained Earnings		 -109 -117 -130 -148 -168 -190 -228
Accumulated Other Comprehensive Income / (Loss)		 -1.86 -1.95 -1.46 -1.25 -0.83 -0.89 -0.84

Quarterly Balance Sheets for Benitec Biopharma

This table presents Benitec Biopharma's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q3 2025 Q1 2026 Q3 2026
Period end date 3/31/2022 9/30/2022 12/31/2022 3/31/2023 9/30/2023 12/31/2024 3/31/2024 9/30/2024 3/31/2025 9/30/2025 3/31/2026
Total Assets		 10 18 12 8.22 27 79 15 69 105 96 187
Total Current Assets		 8.84 17 11 7.40 26 79 14 68 104 95 186
Cash & Equivalents		 8.63 17 11 6.55 26 78 14 68 104 94 185
Restricted Cash		 - 0.01 0.01 0.01 0.01 0.06 0.01 0.06 0.06 0.11 0.11
Accounts Receivable		 0.01 0.00 0.07 0.06 0.05 0.00 0.05 0.00 0.00 0.01 0.00
Prepaid Expenses		 0.21 0.53 0.36 0.77 0.48 0.37 0.16 0.43 0.36 0.48 1.14
Plant, Property, & Equipment, net		 0.21 0.18 0.14 0.11 0.07 0.15 0.20 0.15 0.15 0.12 0.12
Total Noncurrent Assets		 1.01 0.86 0.79 0.72 0.57 0.20 0.43 0.29 1.05 0.83 0.87
Other Noncurrent Operating Assets		 1.01 0.86 0.79 0.72 0.57 0.20 0.43 0.29 1.05 0.83 0.87
Total Liabilities & Shareholders' Equity		 10 18 12 8.22 27 79 15 69 105 96 187
Total Liabilities		 2.54 3.50 2.91 3.51 4.75 3.13 3.50 4.59 7.64 2.43 3.67
Total Current Liabilities		 1.91 3.01 2.49 3.15 4.53 3.09 3.44 4.55 7.03 2.03 3.27
Accounts Payable		 1.32 2.37 1.83 2.46 3.79 2.42 2.63 3.85 6.25 1.15 2.25
Current Employee Benefit Liabilities		 0.36 0.39 0.40 0.43 0.46 0.54 0.52 0.50 0.43 0.46 0.54
Other Current Liabilities		 0.23 0.26 0.26 0.27 0.28 0.14 0.29 0.21 0.35 0.41 0.48
Total Noncurrent Liabilities		 0.64 0.49 0.42 0.35 0.21 0.04 0.06 0.04 0.61 0.40 0.39
Other Noncurrent Operating Liabilities		 0.64 0.49 0.42 0.35 0.21 - 0.06 - 0.61 0.40 0.39
Total Equity & Noncontrolling Interests		 7.52 15 8.99 4.71 22 76 12 64 98 94 183
Total Preferred & Common Equity		 7.52 15 8.99 4.71 22 76 12 64 98 94 183
Preferred Stock		 - - - - - 0.00 - - 0.00 0.00 0.00
Total Common Equity		 7.52 15 8.99 4.71 22 76 12 64 98 94 183
Common Stock		 152 169 169 169 197 279 197 260 310 331 445
Retained Earnings		 -143 -153 -159 -163 -174 -203 -185 -195 -212 -237 -261
Accumulated Other Comprehensive Income / (Loss)		 -1.51 -0.74 -0.90 -0.85 -0.78 -0.69 -0.84 -0.99 -0.72 -0.75 -0.95

Annual Metrics And Ratios for Benitec Biopharma

This table displays calculated financial ratios and metrics derived from Benitec Biopharma's official financial filings.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025
DEI Shares Outstanding		 0.00 0.00 7,854,416.00 - - - 25,600,210.00
DEI Adjusted Shares Outstanding		 0.00 0.00 462,024.00 - - - 25,600,210.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -30.05 - - - -1.48
Growth Metrics		 - - - - - - -
Revenue Growth		 0.00% -99.16% -42.16% 23.73% 2.74% -100.00% 0.00%
EBITDA Growth		 0.00% -401.02% -68.95% -32.20% -7.67% -16.52% -86.32%
EBIT Growth		 0.00% -435.18% -66.46% -30.99% -7.44% -16.01% -85.24%
NOPAT Growth		 0.00% -324.42% -64.18% -31.32% -6.87% -17.87% -85.70%
Net Income Growth		 0.00% -417.13% -67.78% -31.16% -7.44% -11.19% -74.32%
EPS Growth		 0.00% -365.57% 60.12% -31.16% -7.44% 60.98% 13.93%
Operating Cash Flow Growth		 0.00% -257.31% -70.30% -23.90% -13.29% -7.72% -21.57%
Free Cash Flow Firm Growth		 0.00% 0.00% -73.70% -19.04% -10.70% -17.02% -125.47%
Invested Capital Growth		 0.00% -50.11% -48.28% -628.32% -91.62% -60.88% 84.73%
Revenue Q/Q Growth		 0.00% 0.00% 156.52% 0.00% 10.29% -100.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% -7.44% -7.26% 2.17% -4.59% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% -7.32% -6.84% 2.03% -4.56% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% -7.61% -5.20% 0.97% -4.64% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% -8.33% -6.21% 2.03% -0.27% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 22.73% -6.21% 2.03% 33.53% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% -18.60% 1.86% 4.05% 3.97% -26.36%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 6.34% 3.79% -0.77% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 121.36% -7.57% -23.54% -38.59% 0.00%
Profitability Metrics		 - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 0.00% 0.00%
EBITDA Margin		 21.68% -7,805.88% -22,800.00% -24,361.64% -25,530.67% 0.00% 0.00%
Operating Margin		 21.17% -8,118.63% -23,044.07% -24,457.53% -25,441.33% 0.00% 0.00%
EBIT Margin		 20.39% -8,172.55% -23,518.64% -24,898.63% -26,038.67% 0.00% 0.00%
Profit (Net Income) Margin		 21.39% -8,111.76% -23,528.81% -24,942.47% -26,082.67% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 104.91% 99.26% 100.04% 100.18% 100.17% 96.01% 90.35%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 294.86% -882.97% -2,870.95% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 294.70% -863.56% -2,841.44% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 -279.14% 821.30% 2,779.16% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 15.72% -61.67% -91.79% -159.08% -1,268.61% -91.68% -52.46%
Cash Return on Invested Capital (CROIC)		 0.00% -816.10% -2,807.30% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 12.93% -54.09% -84.18% -132.90% -374.23% 0.00% 0.00%
Return on Assets (ROA)		 13.56% -53.69% -84.22% -133.14% -374.86% 0.00% 0.00%
Return on Common Equity (ROCE)		 15.72% -61.67% -91.79% -159.08% -1,268.61% -91.68% -52.46%
Return on Equity Simple (ROE_SIMPLE)		 15.72% -80.82% -69.38% -631.78% 0.00% -46.04% 0.00%
Net Operating Profit after Tax (NOPAT)		 2.58 -5.80 -9.52 -12 -13 -16 -29
NOPAT Margin		 21.17% -5,683.04% -16,130.85% -17,120.27% -17,808.93% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.17% -19.42% -29.51% -47.86% -189.01% -22.49% -11.67%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - -30.05%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 37.82% 5,457.84% 11,037.29% 9,104.11% 8,509.33% 0.00% 0.00%
R&D to Revenue		 37.44% 2,942.16% 11,898.31% 15,441.10% 17,032.00% 0.00% 0.00%
Operating Expenses to Revenue		 78.83% 8,218.63% 23,144.07% 24,557.53% 25,541.33% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 2.49 -8.34 -14 -18 -20 -23 -42
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 2.65 -7.96 -13 -18 -19 -22 -42
Valuation Ratios		 - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 1.67 3.29 33.04 1.39 3.08
Price to Tangible Book Value (P/TBV)		 0.00 0.00 1.67 3.29 33.04 1.39 3.08
Price to Revenue (P/Rev)		 0.00 0.00 565.78 129.85 88.98 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 60.16 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 230.46 74.02 55.78 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.95 -0.95 -0.98 -1.04 -2.13 -1.13 -1.03
Leverage Ratio		 1.16 1.15 1.09 1.19 3.38 1.19 1.05
Compound Leverage Factor		 1.22 1.14 1.09 1.20 3.39 1.15 0.95
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 0.00 5.05 -42.50 -66.20 2.46 74.81
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - -
Current Ratio		 7.10 9.52 15.05 1.90 0.94 10.49 54.67
Quick Ratio		 6.91 8.68 14.46 1.61 0.64 10.38 54.26
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -5.36 -9.31 -11 -12 -14 -32
Operating Cash Flow to CapEx		 1,197.50% -8,015.96% -5,806.33% -122,300.00% -1,801,200.00% -10,839.66% -131,044.44%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - -
Asset Turnover		 0.63 0.01 0.00 0.01 0.01 0.00 0.00
Accounts Receivable Turnover		 4.81 0.08 1.40 5.21 2.59 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 25.96 0.24 0.16 0.24 0.49 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 75.88 4,643.01 259.83 70.00 141.13 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 75.88 4,643.01 259.83 70.00 141.13 0.00 0.00
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 0.88 0.44 0.23 -1.19 -2.29 -3.68 -0.56
Invested Capital Turnover		 13.93 0.16 0.18 -0.15 -0.04 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -0.44 -0.21 -1.42 -1.09 -1.39 3.12
Enterprise Value (EV)		 0.00 0.00 14 5.40 4.18 15 202
Market Capitalization		 0.00 0.00 33 9.48 6.67 65 300
Book Value per Share		 $19.37 $10.03 $2.55 $0.35 $0.01 $5.04 $3.80
Tangible Book Value per Share		 $19.37 $10.03 $2.55 $0.35 $0.01 $5.04 $3.80
Total Capital		 17 10 20 2.88 0.20 47 97
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -16 -9.80 -20 -4.08 -2.49 -51 -98
Capital Expenditures (CapEx)		 0.40 0.09 0.22 0.01 0.00 0.18 0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.40 -0.13 -0.55 -1.79 -2.74 -4.18 -1.14
Debt-free Net Working Capital (DFNWC)		 16 9.67 19 2.29 -0.25 47 97
Net Working Capital (NWC)		 16 9.67 19 2.29 -0.25 47 97
Net Nonoperating Expense (NNE)		 -0.03 2.48 4.36 5.71 6.21 6.01 8.68
Net Nonoperating Obligations (NNO)		 -16 -9.80 -20 -4.08 -2.49 -51 -98
Total Depreciation and Amortization (D&A)		 0.16 0.37 0.42 0.39 0.38 0.34 0.40
Debt-free, Cash-free Net Working Capital to Revenue		 3.25% -125.49% -923.73% -2,449.32% -3,652.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 132.10% 9,483.33% 32,608.47% 3,134.25% -332.00% 0.00% 0.00%
Net Working Capital to Revenue		 132.10% 9,483.33% 32,608.47% 3,134.25% -332.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $51.85 ($137.70) ($54.91) ($37.91) ($14.12) ($5.51) ($1.05)
Adjusted Weighted Average Basic Shares Outstanding		 50.40K 65.20K 480.69K 480.69K 1.39M 4.06M 36.21M
Adjusted Diluted Earnings per Share		 $51.85 ($137.70) ($54.91) ($37.91) ($14.12) ($5.51) ($1.05)
Adjusted Weighted Average Diluted Shares Outstanding		 50.40K 65.20K 480.69K 480.69K 1.39M 4.06M 36.21M
Adjusted Basic & Diluted Earnings per Share		 $51.85 ($137.70) ($54.91) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 50.40K 60.07K 252.67K 480.69K 2.55M 10.56M 26.25M
Normalized Net Operating Profit after Tax (NOPAT)		 1.81 -5.80 -9.52 -12 -13 -16 -29
Normalized NOPAT Margin		 14.82% -5,683.04% -16,130.85% -17,120.27% -17,808.93% 0.00% 0.00%
Pre Tax Income Margin		 21.39% -8,111.76% -23,528.81% -24,942.47% -26,082.67% 0.00% 0.00%
Debt Service Ratios		 - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -5.80% -23.25% 0.00% -9.55% -27.09% -6.12%

Quarterly Metrics And Ratios for Benitec Biopharma

This table displays calculated financial ratios and metrics derived from Benitec Biopharma's official financial filings.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q3 2025 Q1 2026 Q3 2026
Period end date 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2024 3/31/2024 6/30/2024 9/30/2024 3/31/2025 9/30/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - 23,451,475.00 26,250,469.00 33,862,226.00
DEI Adjusted Shares Outstanding		 - - - - - - - - 23,451,475.00 26,250,469.00 33,862,226.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - -0.62 -0.34 -0.35
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -44.00% 12.50% 0.00% 0.00% -100.00% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -12.84% -36.37% 8.51% -17.74% -67.25% 2.61% -21.45% 5.01% -265.29% -76.92% 11.71%
EBIT Growth		 -12.31% -34.46% 7.99% -16.99% -65.57% 2.62% -21.21% 4.79% -258.46% -76.16% 11.71%
NOPAT Growth		 -16.03% -25.46% 3.95% -28.25% -53.48% 4.61% -21.93% 1.41% -270.32% -69.28% 11.43%
Net Income Growth		 -12.24% -34.26% 8.01% -16.91% -35.96% 2.68% -1.27% 15.03% -238.89% -77.21% 17.70%
EPS Growth		 -12.24% -34.26% 8.01% 61.78% 90.12% 38.58% 61.01% 84.26% -65.22% -22.22% 36.84%
Operating Cash Flow Growth		 -74.73% -17.74% 15.65% -13.15% 8.18% -53.09% 19.58% -0.20% 0.00% 26.93% 0.00%
Free Cash Flow Firm Growth		 -202.62% 3.09% -10.29% -62.52% -34.09% 8.80% -19.11% -57.37% -249.19% -146.15% -91.95%
Invested Capital Growth		 -4.29% -66.85% -91.62% -84.54% -54.40% -43.41% -60.88% -4.37% -128.77% 73.34% 74.61%
Revenue Q/Q Growth		 0.00% 285.71% -87.04% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -6.38% 18.92% -6.33% -28.39% -51.11% 37.65% -32.59% -0.41% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 -6.25% 18.73% -5.99% -27.83% -50.37% 37.06% -31.93% -0.41% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 -22.49% 22.62% -4.81% -29.10% -46.58% 40.22% -33.98% -4.38% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 -6.24% 18.74% -6.00% -27.74% -23.56% 37.06% -10.31% -7.18% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 -6.24% 18.74% -6.00% 9.23% 89.18% 37.88% 20.12% 63.36% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 -44.45% 31.05% -1.64% -11.77% -17.22% -14.97% 46.61% -39.27% 0.00% 59.20% 0.00%
Free Cash Flow Firm Q/Q Growth		 -153.48% 40.55% 8.96% -18.45% -109.14% -40.78% -18.90% -56.50% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 19.49% -18.95% -23.54% -55.99% 32.64% 45.99% -38.59% -1.20% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 -37,857.14% -7,957.41% -65,271.43% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 -40,071.43% -8,038.89% -65,000.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 -38,585.71% -8,129.63% -66,471.43% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 -38,650.00% -8,142.59% -66,585.71% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.17% 100.16% 100.17% 100.10% 82.26% 100.09% 83.69% 89.33% 94.63% 89.87% 88.22%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -190.08% -326.46% -1,268.61% -110.63% -52.67% -267.59% -91.68% -48.23% 0.00% -53.01% 0.00%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -184.60% -60.47% -955.32% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 -184.91% -60.57% -956.97% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -190.08% -326.46% -1,268.61% -110.63% -52.67% -267.59% -91.68% -48.23% 0.00% -53.01% 0.00%
Return on Equity Simple (ROE_SIMPLE)		 -209.54% -423.68% 0.00% -91.55% -29.46% -188.63% 0.00% -32.50% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -3.93 -3.04 -3.19 -4.11 -6.03 -2.90 -3.88 -4.05 -11 -6.86 -9.51
NOPAT Margin		 -28,050.00% -5,627.22% -45,500.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -12.97% -17.88% -44.96% -8.68% -2.99% -13.32% -3.13% -2.14% -6.39% -2.59% -1.68%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - -7.94% - - - -11.00% -7.33% -5.19%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 13,307.14% 2,274.07% 19,585.71% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 26,864.29% 5,864.81% 45,514.29% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 40,171.43% 8,138.89% 65,100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -5.40 -4.39 -4.65 -5.95 -8.94 -4.28 -5.64 -5.66 -15 -9.98 -14
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -5.30 -4.30 -4.57 -5.87 -8.86 -4.19 -5.55 -5.57 -15 -9.86 -14
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.53 1.25 33.04 0.35 3.86 1.18 1.39 1.51 3.13 3.93 1.52
Price to Tangible Book Value (P/TBV)		 0.53 1.25 33.04 0.35 3.86 1.18 1.39 1.51 3.13 3.93 1.52
Price to Revenue (P/Rev)		 76.72 86.37 88.98 102.63 4,806.94 1,944.33 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 55.78 0.00 3,522.60 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.15 -1.24 -2.13 -1.15 -1.05 -1.28 -1.13 -1.08 -1.08 -1.03 -1.03
Leverage Ratio		 1.31 1.49 3.38 1.22 1.07 1.43 1.19 1.11 1.10 1.04 1.04
Compound Leverage Factor		 1.31 1.50 3.39 1.22 0.88 1.43 1.00 0.99 1.04 0.94 0.92
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -18.33 -27.93 -55.20 -7.78 53.45 -14.99 3.53 9.53 0.00 88.37 0.00
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 4.41 2.35 0.94 5.83 25.48 4.18 10.49 15.01 14.80 46.95 56.82
Quick Ratio		 4.26 2.10 0.64 5.72 25.34 4.13 10.38 14.90 14.74 46.66 56.43
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -3.86 -2.30 -2.09 -2.48 -5.18 -2.09 -2.49 -3.90 -7.31 -9.59 -14
Operating Cash Flow to CapEx		 0.00% 0.00% -409,500.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 1.70 2.23 2.59 2.68 1.74 0.13 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.30 0.43 0.49 0.61 0.42 0.05 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 214.88 163.71 141.13 136.27 209.43 2,841.79 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 214.88 163.71 141.13 136.27 209.43 2,841.79 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -1.56 -1.85 -2.29 -3.57 -2.40 -2.66 -3.68 -3.73 -6.08 -0.99 -1.54
Invested Capital Turnover		 -0.04 -0.05 -0.04 -0.03 -0.03 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -0.06 -0.74 -1.09 -1.64 -0.85 -0.80 -1.39 -0.16 -3.42 2.73 4.53
Enterprise Value (EV)		 -5.79 -0.69 4.18 -18 215 -0.55 15 29 201 274 95
Market Capitalization		 4.76 5.87 6.67 7.70 293 14 65 97 305 368 280
Book Value per Share		 $0.32 $0.17 $0.01 $8.76 $3.27 $4.44 $5.04 $6.08 $4.16 $3.57 $6.98
Tangible Book Value per Share		 $0.32 $0.17 $0.01 $8.76 $3.27 $4.44 $5.04 $6.08 $4.16 $3.57 $6.98
Total Capital		 8.99 4.71 0.20 22 76 12 47 64 98 94 183
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -11 -6.57 -2.49 -26 -78 -14 -51 -68 -104 -95 -185
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -2.07 -2.32 -2.74 -4.00 -2.72 -3.23 -4.18 -4.12 -6.66 -1.54 -2.13
Debt-free Net Working Capital (DFNWC)		 8.49 4.24 -0.25 22 76 11 47 64 97 93 183
Net Working Capital (NWC)		 8.49 4.24 -0.25 22 76 11 47 64 97 93 183
Net Nonoperating Expense (NNE)		 1.48 1.36 1.48 1.84 1.33 1.38 0.84 1.01 3.77 2.10 2.43
Net Nonoperating Obligations (NNO)		 -11 -6.57 -2.49 -26 -78 -14 -51 -68 -104 -95 -185
Total Depreciation and Amortization (D&A)		 0.10 0.09 0.08 0.08 0.08 0.09 0.09 0.09 0.00 0.12 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 -3,330.65% -3,416.18% -3,652.00% -5,332.00% -4,460.66% -46,100.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 13,687.10% 6,238.24% -332.00% 29,170.67% 123,973.77% 156,128.57% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 13,687.10% 6,238.24% -332.00% 29,170.67% 123,973.77% 156,128.57% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($3.40) ($2.72) ($57.12) ($2.76) ($0.33) ($1.64) ($1.31) ($0.48) ($0.24) ($0.22) ($0.24)
Adjusted Weighted Average Basic Shares Outstanding		 1.62M 1.65M 81.52K 2.16M 22.08M 2.62M 4.06M 10.64M 38.60M 41.52M 49.39M
Adjusted Diluted Earnings per Share		 ($3.40) ($2.72) ($57.12) ($2.76) ($0.33) ($1.64) ($1.31) ($0.48) ($0.24) ($0.22) ($0.24)
Adjusted Weighted Average Diluted Shares Outstanding		 1.62M 1.65M 81.52K 2.16M 22.08M 2.62M 4.06M 10.64M 38.60M 41.52M 49.39M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 ($57.12) $0.00 $0.00 $0.00 ($1.31) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 1.65M 1.65M 149.85K 2.57M 23.45M 9.37M 10.56M 23.22M 25.60M 33.86M 34.35M
Normalized Net Operating Profit after Tax (NOPAT)		 -3.93 -3.04 -3.19 -4.11 -6.03 -2.90 -3.88 -4.05 -11 -6.86 -9.51
Normalized NOPAT Margin		 -28,050.00% -5,627.22% -45,500.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 -38,650.00% -8,142.59% -66,585.71% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -9.92% -9.36% -9.55% -14.51% -13.25% -13.66% -27.09% -14.04% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Benitec Biopharma (NASDAQ: BNTC) continues to operate as a pre-revenue development-stage biotech, with losses funded primarily by cash on hand and periodic financing. The latest quarter shows a very strong cash position, but also ongoing operating losses and a history of dilution.

  • Cash remains exceptionally high: Benitec ended Q3 2026 with $184.8 million in cash and equivalents, up from $94.5 million in Q1 2026 and $103.6 million in Q3 2025.
  • Balance sheet is now very strong: Total equity was $183.3 million in Q3 2026 versus just $97.6 million a year earlier, reflecting the company’s strengthened capital base.
  • Debt appears minimal: Total liabilities were only $3.7 million in Q3 2026, leaving the company with a large net cash position.
  • Interest and investment income helped offset losses: Q3 2026 interest and investment income was $1.6 million, which partially cushioned the operating loss.
  • Operating cash burn has improved materially versus 2025: Q1 2026 operating cash outflow was $3.4 million, better than the $8.2 million outflow in Q4 2025 and the $4.6 million outflow in Q1 2025.
  • Quarterly revenue remains essentially nonexistent: Most recent periods show $0 revenue, indicating the company is still in the development stage.
  • Research spending remains meaningful: Q3 2026 R&D expense was $6.3 million, consistent with an active pipeline but also a sign of ongoing cash consumption.
  • Stock-based or financing-related share counts have shifted over time: Weighted average shares outstanding have moved higher in recent periods, which can matter for future per-share value.
  • The company is still loss-making: Q3 2026 net loss was $11.9 million, following a $9.0 million loss in Q1 2026 and $16.1 million in Q4 2025.
  • Operating expenses are still heavy relative to zero revenue: Q3 2026 operating expenses totaled $13.6 million, driven by SG&A and R&D.
  • Historical dilution has been substantial: Share counts and common equity have risen sharply over the last several years, suggesting financing has come with meaningful dilution for shareholders.

Bottom line: Benitec Biopharma’s financial picture has improved dramatically on the liquidity side, and the company now has a sizable cash cushion. That lowers near-term balance sheet risk. However, it remains a clinical-stage biotech with no meaningful revenue and ongoing losses, so the investment case still depends heavily on pipeline progress and future financing needs.

07/21/26 05:08 AM ETAI Generated. May Contain Errors.

Benitec Biopharma Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Benitec Biopharma's fiscal year ends in June. Their fiscal year 2025 ended on June 30, 2025.

Benitec Biopharma's net income appears to be on an upward trend, with a most recent value of -$37.92 million in 2025, falling from $2.61 million in 2019. The previous period was -$21.75 million in 2024. Check out Benitec Biopharma's forecast to explore projected trends and price targets.

Benitec Biopharma's total operating income in 2025 was -$41.77 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $41.77 million

Over the last 6 years, Benitec Biopharma's total revenue changed from $12.20 million in 2019 to $0.00 in 2025, a change of -100.0%.

Benitec Biopharma's total liabilities were at $2.30 million at the end of 2025, a 53.7% decrease from 2024, and a 13.0% decrease since 2019.

In the past 6 years, Benitec Biopharma's cash and equivalents has ranged from $2.48 million in 2023 to $97.74 million in 2025, and is currently $97.74 million as of their latest financial filing in 2025.

Over the last 6 years, Benitec Biopharma's book value per share changed from 19.37 in 2019 to 3.80 in 2025, a change of -80.4%.


Related Companies

Financial statements for NASDAQ:BNTC last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Elon’s new "tollbooth"
The SpaceX IPO was valued at $1.75 trillion. But one analyst says fighting over those shares may be the wrong ...
Weiss Ratings | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel